Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBA versus insulin glargine in a basal-bolus regimen for type 1 diabetes
2008-005774-13Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diabetes mellitus type 1 (T1D) comparing SIBA + insulin aspart with insulin glargine + insulin aspart (2 arms). Primary endpoints: Change from baseline in HbA1c after 52 weeks of treatment and Non-inferiority of SIBA + insulin aspart versus insulin glargine + insulin aspart on HbA1c at 52 weeks. Started Apr 2009; status: completed.
02
Drugs
insulin degludecinsulin glargineinsulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2008-005774-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005774-13.